Drugs / Mebendazole
Mebendazole
also known as
MBZ · Emverm · MBD · Mebendazol · Mebendazole polymorph c · Mebendazolum · Mebenvet · NSC-184849 · +8 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VERMOX | — | 1974-06-28 | fda.gov ↗ |
Trials 22 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 10 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06720259 Comparator | Apr → May 2025 | ascariasis, hookworm infectious disease, trichuriasis | Jennifer Keiser | Completed | No outcome recorded |
| Phase 2 | NCT03757403 Background | May → Nov 2020 | — | RDD Pharma Ltd | Withdrawn | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06800248 Comparator | Sep 2026 → Apr 2027 expected | ascariasis, hookworm infectious disease, trichuriasis | Swiss Tropical & Public Health Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06736691 Comparator | Nov 2025 → Jul 2026 overdue | ascariasis, hookworm infectious disease, trichuriasis | Swiss Tropical & Public Health Institute | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT02034162 Comparator | Dec 2014 → Sep 2015 | helminthiasis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03245398 Comparator | Jul → Sep 2017 | hookworm infectious disease | Jennifer Keiser | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT06335160 Comparator | Apr 2024 → Apr 2026 overdue | ulcerative colitis | Tanta University | Recruiting | No outcome recorded |
| — | NCT02876146 Background | Jun 2012 → Aug 2021 | alveolar echinococcosis | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| — | NCT01050452 Comparator | Oct 2007 → Aug 2009 | parasitic infectious disease | DBL -Institute for Health Research and Development | Completed | No outcome recorded |
| — | NCT01050374 Comparator | Oct 2007 → Oct 2008 | parasitic infectious disease | DBL -Institute for Health Research and Development | Completed | No outcome recorded |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mebendazole | “Participants were randomly assigned to one of three treatment arms. On the first and third days, all participants got albendazole 400 mg, and on the second day, albendazole...” PMID 38563751 ↗ Apr 202430“Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole” NCT02366884 ↗ “Albendazole treatment, 400 mg x 2/d (or mebendazole if adverse effects)” NCT02876146 ↗ “Oral Mebendazole 100mg uid, for study duration.” NCT02201381 ↗ |
| Known as | Emverm | ChEMBL registry synonym — accepted as the source's own label CHEMBL685 ↗ |
| Known as | MBD | “This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of albendazole (ALB), mebendazole (MBD) and ivermectin (IVM) separately, and ALB...” NCT01050452 ↗ |
| Known as | MBZ | “Purpose: To assess the efficacy of three proposed anthelminthic combination regimens for the treatment of strongyloidiasis using real-time polymerase chain reaction (real-time...” PMID 41364144 ↗ Dec 20252“A randomised clinical trial was conducted in Kabale District, southwestern Uganda, to compare the efficacies of single and double doses of a combination of 400mg albendazole...” PMID 21885077 ↗ Aug 2011 “The primary objective is: (1) to monitor the efficacy a single dose 500 mg of mebendazole (MBZ) against Soil-Transmitted Helminths (STH) infections by means of Faecal Egg...” NCT01379326 ↗ |
| Known as | Mebendazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL685 ↗ |
| Known as | Mebendazole polymorph c | ChEMBL registry synonym — accepted as the source's own label CHEMBL685 ↗ |
| Known as | Mebendazolum | ChEMBL registry synonym — accepted as the source's own label CHEMBL685 ↗ |
| Known as | Mebenvet | ChEMBL registry synonym — accepted as the source's own label CHEMBL685 ↗ |
| Known as | NSC-184849 | ChEMBL registry synonym — accepted as the source's own label CHEMBL685 ↗ |
| Known as | Ovitelmin | ChEMBL registry synonym — accepted as the source's own label CHEMBL685 ↗ |
| Known as | Pantelmin | ChEMBL registry synonym — accepted as the source's own label CHEMBL685 ↗ |
| Known as | R 17,635 | ChEMBL registry synonym — accepted as the source's own label CHEMBL685 ↗ |
| Known as | ReposMBZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03628079 ↗ |
| Known as | Telmintic | ChEMBL registry synonym — accepted as the source's own label CHEMBL685 ↗ |
| Known as | Vermicidin | ChEMBL registry synonym — accepted as the source's own label CHEMBL685 ↗ |
| Known as | Vermox | ChEMBL registry synonym — accepted as the source's own label CHEMBL685 ↗ |
| Known as | Zhihuanqing | ChEMBL registry synonym — accepted as the source's own label CHEMBL685 ↗ |
| Action | Inhibit | “Mebendazole has broad range of action by not only inhibiting angiogenesis and pro-survival pathways of MAPK” NCT04443049 ↗ |
| Modality | Small molecule | “A Randomized Controlled Clinical Trial (RCT) cohort study, to evaluate the efficacy and safety of three benzimidazole derivates drug (Albendazole, Mebendazole, Albendazole...” NCT04326868 ↗ |
| Route | Oral | “route= oral use.” NCT01173562 ↗ |